Pigmentation Disorder Treatment Market Size, Share, Forecast and outlook (2024-2031)

Pigmentation Disorder Treatment Market is segmented By Disease Type (Hyperpigmentation, Market Attractiveness Index, Hypopigmentation (Vitiligo, Post-inflammatory Hypopigmentation and others), By Treatment (Topical Drugs, Chemical Peels, Microdermabrasion, Laser therapy, Phototherapy), By End-User (Hospital, Dermatology Clinics, Aesthetic Clinics, Retail Pharmacies, Online Store), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

Pigmentation Disorders Treatment Market is expected to reach at a CAGR 7.3% during the forecast period (2024-2031).

Pigmentation disorders comprise many diverse conditions, usually characterized by altered melanocyte density, melanin concentration, or both, and result in altered pigmentation of the skin. Some of these disorders are very common, whereas others are rare. Pigmentation disorders are classified as hypopigmentation and hyperpigmentation. In hypopigmentation, the pigment is decreased, whereas, in depigmentation, the pigment is completely lost, leaving white skin.

Pigmentation Disorder Treatment Market Scope

For More Insights - Request Free Sample

Pigmentation Disorder Treatment Market Dynamics

The pigmentation disorders treatment market growth is driven by the rising prevalence of pigmentation disorders, along with the growing expenditure on dermatological treatments.

The rising prevalence of pigmentation disorders is expected to drive the growth in the forecast period

Typical pigmentation disorders include post-inflammatory hyperpigmentation, melasma, solar lentigines, ephelides (freckles), vitiligo, and café au lait macules. These conditions are generally benign but can be distressing to patients.

Appropriate dermatologic history, skin examination, and skin biopsy can help exclude melanoma and its precursors. In addition to addressing the underlying condition, pigmentation disorders are treated with topical agents, chemical peels, cryotherapy, light or laser therapy, or a combination of these methods.

According to a research article published in the International Journal of Molecular Sciences in 2018, a high prevalence of pigmentary disorders in dark-skinned people (South/Southeast Asian, Hispanic/Latin American, African descent) has been reported. Also, pigmentary disorders are the third and fourth more common dermatoses in Blacks and Hispanics, respectively. Thus, the high prevalence of pigmentation disorders is expected to boost the market.

High cost of cosmetic procedures is hampering the market growth

A survey by the American Society of Plastic Surgeons found that in 2014, average surgeon fees for cosmetic procedures nationwide were: Botox $ 385 Eyelid surgery (blepharoplasty) $ 3,022 Cheek implants $ 2,823 Facelift (rhytidectomy) $ 7,048 Chemical peel $ 673 Forehead/brow lift $ 3,403 Chin augmentation $ 2,225. These all factors may restrict the market growth.

COVID-19 Impact on Pigmentation Disorder Treatment Market

The COVID-19 has impacted the pigmentation disorder treatment market. According to a survey by Hamilton Fraser Cosmetic Insurance, in March 2020, with 1,360 cosmetic practitioners in the United Kingdom to assess the pandemic's impact, 99.78% said that their practice had been affected by the pandemic outbreak. During the COVID-19 crisis, there is a need to triage the patients and avoid unnecessary admission related to minor trauma and other ailments. There is also a need not to call the patients to the hospital as far as possible for regular check-ups and minor issues. Although non-urgent clinics and surgical procedures need to be postponed until the situation improves, the hospital must ensure the quality of care provided to the patients. As most cosmetic procedures can be categorized as non-essential, the studied market has been hugely affected.

Pigmentation Disorder Treatment Market Segmentation Analysis

The albinism segment is expected to hold the largest share in this market segment

Albinism is a group of inherited disorders that results in little or no production of the pigment melanin, which determines the color of the skin, hair, and eyes. Melanin also plays a role in the development of certain optical nerves, so all forms of albinism cause problems with the development and function of the eyes. The prevalence of albinism varies across the world. According to the World Health Organization, estimates vary from 1 in 5,000 to 1 in 15,000 people in Sub-Saharan Africa. According to the NGO Under the Same Sun in Europe and North America, 1 in 20,000 people has the condition.

The glycerol phenylbutyrate segment is expected to hold the largest share in this market segment

Currently, the topical treatment segment is dominating the global market due to the improved clinical outcomes in patients suffering from pigmentation disorders. The most common topical drugs prescribed globally are azelaic acid, hydroquinone, L-ascorbic acid, etc. Topical treatment includes topical application of creams, lotions, ointments, and serums that are formulated using various active ingredients to treat different pigmentation conditions.

As per the National Clinical Trials (NCT) registry, as of June 18, 2020, Incyte Corporation is conducting a clinical trial for Ruxolitinib in the treatment of Vitiligo which is in phase II development in the United States. This factor will boost the market if the Ruxolitinib drug gets approved for the treatment of Vitiligo in the near future.

Additionally, topical corticosteroids (TC) application to treat pigmentation disorders is one of the most successful treatment options. Some of the commonly used corticosteroids are fluticasone propionate, betamethasone valerate, and hydrocortisone butyrate, among others. According to the February 2021 research article published in the Journal of Investigative Dermatology titled “Efficacy and Safety of Tacrolimus 0.1% for the Treatment of Facial Vitiligo”, results demonstrated that usage of twice-daily tacrolimus 0.1% ointment showed superior efficacy with 65% Therapeutic success in 42 tacrolimus-treated patients.

According to the June 2019 research article published on SCIENCE DAILY by researchers from Tufts Medical Center in Boston, results demonstrated that Topical ruxolitinib cream was extremely effective in reversing the effects of vitiligo. The development of these therapies holds the promise to increase the accessibility of an effective, non-invasive treatment option for hand tremors. Thus, all these developments currently happening in the market are expected to offer immense growth opportunities to the segment. As the aging process modifies the pigmentary system, and uneven pigmentation is one of the major changes associated with aging, which may lead to increased demand for topical treatments in an aging population.

Pigmentation Disorder Treatment Market Geographical Share

North America region holds the largest market share of the global pigmentation disorders treatment market

North America dominates the global pigmentation disorders treatment market owing to the rising pigmentation disorders. Presence of well-established healthcare infrastructure and major market players providing effective treatment options to the patients suffering from post-inflammatory hyperpigmentation in North America. As per the National Organization for Albinism and Hypopigmentation 2018, in the United States, about one in 18,000 to 20,000 people had some type of albinism. In other parts of the world, the occurrence can be as high as one in 3,000. For instance, according to the National Clinical Trials (NCT) Registry, as of June 21st, 2021, in the United States, there were 19 vitiligo related trials under development (with the status ‘'Active, not recruiting'’, ‘'Enrolling by invitation'' and ‘'Recruiting’', which is expected to show a positive impact on the market studied. Since vitiligo is a very common skin pigmentation disorder, increasing trials is expected to provide more treatment options, thus aiding demand.

In addition, the presence of some of the leading market players, such as Obagi Cosmeceuticals, Alvogen, and AbbVie Inc., is expected to boost market growth due to the availability of different products. Various strategies, such as research and development, mergers and acquisitions, and product launches, are adopted by domestic companies to strengthen their market position. In January 2020, Eli Lilly signed a definitive agreement to acquire the dermatological drug's developer, Dermira, in a USD 1.1 billion all-cash deal, adding commercial and late-stage drugs to its portfolio. This is expected to boost its dermatological treatment pipeline. Thus, the market for pigmentation disorders treatment in the North American region is expected to grow at a decent rate over the forecast period.

Pigmentation Disorder Treatment Companies and Competitive Landscape

Pigmentation Disorders Treatment Market is moderately competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include AbbVie Inc (Allergan, Inc), Episciences, Inc, DermaMed Solutions, LLC, L'Oreal S.A, Pierre Fabre Group (Pierre Fabre Laboratories), Vital Esthetique, Obagi Cosmeceuticals LLC, Pfizer Inc., Galderma S.A, Merz GmbH & Co. KGaA. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in July 2019, Dermatix, a brand of A. Menarini Singapore Pte Ltd has just launched its new acne scar care, Dermatix Acne scar consisting of snail slime extract and Hyaluronic Acid combating post-acne skin discoloration, the treatment gel contains Niacinamide (Vitamin B3) to reduce hyperpigmentation.

Pigmentation Disorders Treatment Market Key Companies to Watch

DermaMed Solutions, LLC

Overview: DermaMed Solutions provides aesthetic equipment, natural skincare products, wellness regimens, and more for skincare professionals, spa owners, dermatologists, estheticians, and plastic surgeons. Dermamed Solutions, LLC is a Lenni, Pennsylvania Foreign LLC filed on 1998.

Product Portfolio: The Company’s portfolio comprised of includes medical devices, professional skincare products, nutrition consultation, wellness training, microdermabrasion machines, hair removal machines - IPL and diode laser, spa equipment, medical spa marketing materials, and aesthetic equipment.

Key Developments: Mark Pinsley and his business partner acquired DermaMed Solutions in July 2011, and the company has grown into a nationally-recognized provider of state-of-the-art Microdermabrasion and other aesthetic equipment and grown the professional skincare products to the current dmSkincare line of professional and retail products which offer nutritious, botanically-based skincare to support and enhance microdermabrasion and other mechanical treatment protocols.